We hypothesized that treatment-related weight loss is associated with worse outcomes following HSCT. Overall, 184 patients with AML who underwent induction therapy were classified according to d-BMI (BMI at transplant minus BMI at diagnosis) (kg/m2) as < -2, - 2 to + 2, and > + 2. At 1 year, OS was 67.9% (95% CI, 60.7-74.2), DFS was 64.1% (95% CI, 56.7-70.6), and GRFS was 40.2% (95% CI, 33.1-47.2). For d-BMI groups < - 2, - 2 to + 2, and > + 2, GRFS at 1 year was 16.1% (95% CI, 5.1-31.4), 45.4% (95% CI, 36.4-53.7), and 41.7% (95% CI, 22.2-60.1), respectively (P = 0.0067). Multivariate analysis showed that both worse OS (HR, 1.78; 95% CI, 1.02-3.14; P = 0.007) and GRFS (HR, 2.34; 95% CI, 1.26-4.35; P = 0.007) were associated with reduced BMI (d-BMI < - 2). Treatment-related weight reduction in AML was associated with poor outcome after HSCT.

中文翻译：

---

从诊断到造血干细胞移植，与治疗有关的体重变化对急性髓细胞性白血病临床预后的影响。

我们假设与治疗相关的体重减轻与HSCT后的预后不良有关。总体上，根据d-BMI（移植时的BMI减去诊断时的BMI）（kg / m2）将184例接受诱导治疗的AML患者分类为<-2，-2至+ 2和> + 2。 ，OS为67.9％（95％CI，60.7-74.2），DFS为64.1％（95％CI，56.7-70.6），GRFS为40.2％（95％CI，33.1-47.2）。对于d-BMI组<-2，-2至+ 2和> + 2，一年的GRFS为16.1％（95％CI，5.1-31.4），45.4％（95％CI，36.4-53.7）和分别为41.7％（95％CI，22.2-60.1）（P = 0.0067）。多变量分析显示，较差的OS（HR，1.78; 95％CI，1.02-3.14; P = 0.007）和GRFS（HR，2.34; 95％CI，1.26-4.35; P = 0.007）与BMI降低相关（d -BMI <-2）。